Lung Disease Clinical Trial
Official title:
Comparative Study of the Non-dependent Continuous Positive Airway Pressure and High-frequency Positive-pressure Ventilation on Fluid Responsiveness During One-lung Ventilation for Thoracoscopic Surgery
The stroke volume variation (SVV), measured using the Vigileo-FloTrac system (Edwards
Lifescience, Irvine, CA), has been shown to able to predict fluid responsiveness during
one-lung ventilation (OLV) in patients undergoing pulmonary lobectomy (sensitivity: 82.4%,
specificity: 92.3%).1 Many parameters such as tidal volume (TV),1-2 positive end-expiratory
pressure (PEEP),3 respiratory rate (RR), 4 chest and lung compliance,5 heart rate and rhythm,
and ventricular function and afterload,6-7 all have been documented to have effects on the
SVV.
SVV is calculated as the variation of beat-to-beat SV from the mean value during the most
recent 20 seconds of data: SVV = (SVmax − SVmin)/SVmean, where SVmax, SVmin, and SVmean are,
respectively, the maximum, minimum, and mean SV determined by the system.
SVV may not be sufficiently sensitive to predict fluid responsiveness in patients with right
ventricular (RV) dysfunction due to concomitant increases in RV afterload, that lead to a
decrease in preload variation and subsequent inaccuracy in SVV measurements.8
OLV may increase airway pressure, resulting in increases in the RV afterload, end-diastolic
volume, and stroke work index, thus impeding RV function.9-11The increases in the right
ventricular afterload may exaggerate the cyclic variation in stroke volume.12
In the authors' previous study,9 they found that the high-frequency positive-pressure
ventilation (HFPPV) was superior to continuous positive-airway pressure (CPAP) for OLV,
resulting in significantly higher RV ejection fraction, lower RV afterload and higher
arterial oxygenation, whereas the former limiting the adequate operative field visualization
during video-assisted thoracoscopic surgery (VATS).13
The effects of the nondependent lung ventilation with HFPPV and CPAP on the SVV and fluid
responsiveness during OLV has not yet been studied.
Status | Not yet recruiting |
Enrollment | 62 |
Est. completion date | June 2020 |
Est. primary completion date | April 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - American Society of Anesthesiologists physical class of II to III - Duration of OLV is expected to exceed 1.5 hours Exclusion Criteria: - New York Heart Association class > II - Right ventricular dysfunction - Pulmonary hypertension - valvular heart disease - intracardiac shunts - Any cardiac rhythm other than sinus - Hypertension - Diabetes mellitus - Renal dysfunction - Hepatic dysfunction - Pregnancy - Body mass index >35 kg m-2 - Peripheral arterial occlusive disease - preoperative administration of inotropic medications |
Country | Name | City | State |
---|---|---|---|
Saudi Arabia | King Fahd Hospital of the University | Khobar | Eastern |
Lead Sponsor | Collaborator |
---|---|
Dammam University |
Saudi Arabia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Fluid responsiveness | To explore the ability of SVV to predict fluid responsiveness with ROC plots | 5 min after volume loading | |
Secondary | Heart rate | 5 min before volume loading, 5 min after volume loading | ||
Secondary | Stroke volume variation | 5 min before volume loading, 5 min after volume loading | ||
Secondary | Mean blood pressure | 5 min before volume loading, 5 min after volume loading | ||
Secondary | Cardiac index | 5 min before volume loading, 5 min after volume loading | ||
Secondary | Stroke Volume Index | 5 min before volume loading, 5 min after volume loading | ||
Secondary | Airway pressures | 5 min before volume loading, 5 min after volume loading | ||
Secondary | Lung Compliance | 5 min before volume loading, 5 min after volume loading |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02217423 -
Abdominal Circumference and Cardiorespiratory Repercussions in Patients Submitted to Physical Therapy
|
N/A | |
Withdrawn |
NCT02253667 -
Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients
|
N/A | |
Completed |
NCT01679301 -
Evaluation of Sleep Mode Within the Respironics SimplyGo Portable Oxygen Concentrator
|
N/A | |
Completed |
NCT02345135 -
Susceptibility to Infections in Ataxia Telangiectasia
|
N/A | |
Terminated |
NCT00966823 -
Fetal Tracheal Balloon Study in Diaphragmatic Hernia
|
Phase 2 | |
Completed |
NCT00139152 -
Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair
|
Phase 4 | |
Completed |
NCT00052052 -
An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
Completed |
NCT00013949 -
Cardiovascular Vulnerability to Particulate Exposure
|
N/A | |
Recruiting |
NCT02963467 -
Effect of Smoking on Ventilation-Perfusion Ratio
|
N/A | |
Recruiting |
NCT02965300 -
The Value of VOCs Analysis in Exhaled Breath for Pulmonary Benign and Malignant Lesion Diagnosis
|
N/A | |
Enrolling by invitation |
NCT02946658 -
Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT02913365 -
Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis
|
N/A | |
Completed |
NCT01952002 -
Clinical Safety for the Inspiratory Muscle Training
|
N/A | |
Completed |
NCT01735526 -
Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide After Hematopoietic Stem-cell Transplantation
|
N/A | |
Recruiting |
NCT01450644 -
Evaluation of the Hospital2Home Palliative Care Service for Patients With Advanced Progressive Lung Disease
|
Phase 2 | |
Completed |
NCT01215279 -
AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)
|
Phase 2 | |
Completed |
NCT01153321 -
Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Completed |
NCT00837681 -
Pulmonary Complications of Hematopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT02055222 -
Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease
|
||
Completed |
NCT01222442 -
To Evaluate the Effect of AZD3199 on the Electrical Activity in the Heart
|
Phase 1 |